Medpredict, Feb 2010, Pages: 146
amongst the most important mechanisms in development for ovarian cancer. Executive Summary
Top-Ten Report Highlights
- Key Findings
- Ovarian Cancer Standards of Care / Unmet Needs
- Subtypes
Datamonitor, Nov 2011, Pages: 166
(temsirolimus; Pfizer)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Tykerb (lapatinib; GlaxoSmithKline)
Drug
Decision Resources, Inc., Dec 2006, Pages: 24
’ SGN-30 19
Agents in Development for Mantle Cell Lymphoma 19
Wyeth’s Temsirolimus 19
Genta’s Genasense 19
Millennium Pharmaceuticals’ Velcade 19
Agents in Development for Relapsed or Refractory NHL 20
Datamonitor, Oct 2011, Pages: 100
blockbuster targeted therapies will undergo patent expiries and the market will become more fragmented as new targeted therapies are developed for niche populations.
Features and benefits
- Sales forecasts
Informa Healthcare, Jan 2007
levels of the industry and recent developments.
Scrip Yearbook 2008 will help you to:
- Identify which significant mergers and acquisitions were completed
- Analyse the strategic and financial
GlobalData, June 2011, Pages: 82
disease markets in the long run.
Reasons to buy
The report will serve to facilitate your decision making in the concerned therapy areas. It will allow you to -
- Develop business strategies
